AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
11.49
-0.13 (-1.12%)
At close: Nov 13, 2026, 4:00 PM EST
11.52
+0.03 (0.26%)
After-hours: Nov 13, 2026, 7:59 PM EST
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $10.64M in the quarter ending September 30, 2026, with 18.81% growth. This brings the company's total for the last twelve months to $67.86M, up 92.10% year-over-year. In the year 2025, AbCellera Biologics had annual revenue of $75.13M with 160.56% growth. That makes AbCellera Biologics the 25,693rd largest company in the world by revenue and 3,557th in the United States.
Revenue (ttm)
$67.86M
Revenue Growth
+92.10%
P/S Ratio
54.87
Revenue / Employee
$120,737
Employees
562
Market Cap
3.72B
Revenue by Segment
- Licensing and Royalty 46.92M 62.5%
- Research Fees 27.21M 36.2%
- Milestone Payments 1.00M 1.3%
Fiscal year ended Dec 31, 2025 See the full AbCellera Biologics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75.13M | 46.30M | 160.56% |
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
| Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
| Dec 31, 2019 | 11.61M | 2.78M | 31.49% |
| Dec 31, 2018 | 8.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.36B |
| Tarsus Pharmaceuticals | 682.20M |
| Arcutis Biotherapeutics | 508.68M |
| Iovance Biotherapeutics | 378.98M |
| Viridian Therapeutics | 26.31M |
| CRISPR Therapeutics AG | 25.17M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
ABCL News
- 3 days ago - AbCellera price target raised to $15 from $11 at StoneX - TheFly
- 3 days ago - AbCellera Biologics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 4 days ago - AbCellera reports Q3 EPS (19c), consensus (18c) - TheFly
- 4 days ago - AbCellera price target raised to $14 from $9 at Stifel - TheFly
- 5 days ago - AbCellera Biologics Earnings Call Transcript: Q3 2026 - Transcripts
- 5 days ago - AbCellera Biologics Slides: Q3 2026 - Filings
- 5 days ago - AbCellera Biologics Earnings release: Q3 2026 - Filings
- 5 days ago - AbCellera Biologics Quarterly report: Q3 2026 - Filings